Theratechnologies Inc. Logo

Theratechnologies Inc.

Biopharma company commercializing therapies for multi-drug resistant HIV and lipodystrophy.

THTX | US

Overview

Corporate Details

ISIN(s):
CA88338H1001 (+1 more)
LEI:
Country:
United States of America
Address:
2015 PEEL STREET, 0 MONTREAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Theratechnologies Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative therapies that address unmet medical needs, particularly within the field of Human Immunodeficiency Virus (HIV). The company's commercial portfolio includes two key products approved in the United States: Trogarzo®, a monoclonal antibody for treating multi-drug resistant HIV-1, and EGRIFTA SV®/EGRIFTA WR™ (tesamorelin), a therapy for reducing excess abdominal fat in adults with HIV and lipodystrophy. In September 2025, the company announced the completion of its acquisition by Future Pak.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Theratechnologies Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Theratechnologies Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Theratechnologies Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Foghorn Therapeutics Inc. Logo
Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.
United States of America
FHTX
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany
FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America
FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America
GUTS
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy
FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan
4554
Fulcrum Therapeutics, Inc. Logo
Develops gene-modulating small molecule drugs for rare, genetically defined diseases.
United States of America
FULC
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan
4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea
220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea
341170

Talk to a Data Expert

Have a question? We'll get back to you promptly.